stockrow
Saturday 7 November 2026
Export KLRA’s income statement to Excel — free account
Kailera Therapeutics, Inc.
KLRA Healthcare Biotechnology
- EPS
- +100.0%
- Free cash flow
- −326.0%
Quarter to September 2026, against a year earlier
12.97
0.80
+6.57%
Follow KLRA
Alert me
Kailera Therapeutics, Inc. (KLRA) P/E ratio
Kailera Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ABSI Absci Corporation compare | n/m |
| SLS SELLAS Life Sciences Group, Inc. compare | n/m |
| GENB Generate Biomedicines, Inc. compare | n/m |
| RARE Ultragenyx Pharmaceutical Inc. compare | n/m |
| KLRA Kailera Therapeutics, Inc. | n/m |
| NTLA Intellia Therapeutics, Inc. compare | n/m |
| NVAX Novavax, Inc. compare | n/m |
| NRIX Nurix Therapeutics, Inc. compare | 6.1× |
| BRVE Braveheart Bio, Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)